Understanding ADC Charge Variants to Enable Effective CQA Assessment & Control Strategy - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Understanding ADC Charge Variants to Enable Effective CQA Assessment & Control Strategy

2:30 pm - Monday 12th October 2026

Understanding the sources and impacts of ADC charge variant profiles given impact from linker-payload properties
Undergoing CQA assessments to determine ADC clinical relevance
Defining compound-specific, phase-appropriate and value-focused control strategies

Speakers:

Hao Luo

Hao Luo

Associate Scientific Director

Bristol Myers Squibb